{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:06:32Z","timestamp":1790060792576,"version":"4.0.1"},"reference-count":35,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101RAs) are widely used for Type 2 diabetes (T2DM) and obesity, but emerging evidence links them to nonarteritic anterior ischemic optic neuropathy (NAION). Whether this risk differs across agents and the underlying mechanisms remains unclear. We aimed to compare the risks of NAION associated with different GLP\u20101RAs and to explore the potential molecular mechanisms underlying this adverse reaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>A network meta\u2010analysis was performed to quantitatively compare the differences in NAION risk. Real\u2010world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) were used for validation. Network toxicology was further applied to identify central hub targets and signalling pathways. Molecular docking was conducted to evaluate the binding capacity of GLP\u20101RAs to central hub targets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The network meta\u2010analysis revealed significant differences in NAION risk across GLP\u20101RAs. Compared with non\u2010GLP\u20101RA treatments, semaglutide showed the highest risk (HR\u2009=\u20091.538, 95% CI: 1.305\u20131.816), followed by liraglutide (HR\u2009=\u20091.251, 95% CI: 1.080\u20131.450). FAERS pharmacovigilance analysis suggested a strong disproportionate signal for semaglutide (ROR\u2009=\u200994.534, 95% CI: 83.093\u2013107.552) and a statistically significant but weaker signal for liraglutide (ROR\u2009=\u20094.519, 95% CI: 2.617\u20137.802). Network toxicology identified CASP3 as the central hub target, and pathway enrichment analysis revealed that the underlying mechanisms were primarily related to Alzheimer's disease, neurodegeneration pathways, and lipid and atherosclerosis pathways. Molecular docking suggested that semaglutide and liraglutide had high binding affinity to CASP3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combined strategy of network meta\u2010analysis, pharmacovigilance, network toxicology and molecular docking provides insights into possible risk differences and potential mechanisms, and may guide future research on the safety profile of GLP\u20101RAs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71358","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:32:42Z","timestamp":1790058762000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon\u2010Like Peptide\u20101 Receptor Agonists: An Integrated Safety and Mechanistic Analysis"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9015-0480","authenticated-orcid":false,"given":"Hong","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pharmacy Eye &amp; ENT Hospital, Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Eye &amp; ENT Hospital, Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchao","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Eye &amp; ENT Hospital, Fudan University  Shanghai China"},{"name":"Clinical Trial Institution, Eye &amp; ENT Hospital, Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taomin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Eye &amp; ENT Hospital, Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/vision7040072"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2500106"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci24\u20100003"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70406"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2026.101740"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214864"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/19322968241268050"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.2296"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.05.007"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020\u2010024\u201004112\u20108"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26321"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.0349"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/usaf522"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14\u20102385"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad976"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae883"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baq020"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.62407"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae1113"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf379"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.6555"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.10.030"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.2299"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942\u2010024\u201000620\u2010x"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.6262"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2026.02.002"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16316"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70200"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/bab.2233"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2007.05.024"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI76246"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27156981"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/10799893.2020.1833921"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209657"},{"key":"e_1_2_10_36_1","first-page":"963","article-title":"Oligodendrocyte Death, Neuroinflammation, and the Effects of Minocycline in a Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy (rNAION)","volume":"23","author":"Mehrabian Z.","year":"2017","journal-title":"Molecular Vision"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71358","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71358","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71358","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:32:43Z","timestamp":1790058763000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":35,"alternative-id":["10.1111\/dom.71358"],"URL":"https:\/\/doi.org\/10.1111\/dom.71358","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"2026-07-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"dom.71358"}}